Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma will showcase data from multiple obesity drug candidates at the 33rd European Congress on Obesity in Istanbul in May 2026, underscoring its ambitions in the competitive weight-loss therapeutics space. Key highlights include Phase I data for ASC47, an adipose-targeting THRβ agonist, which, when combined with semaglutide, achieved up to 111.8% greater relative weight loss in obese participants than semaglutide alone.
The company will also present preclinical results for ASC36, a once-monthly next-generation amylin receptor agonist peptide that showed a six-fold longer half-life and markedly higher relative weight loss than petrelintide in animal models. A third program, ASC35, a once-monthly GLP-1R/GIPR dual agonist peptide, demonstrated a six-fold longer half-life than tirzepatide and substantially greater weight-loss efficacy in preclinical models, highlighting Ascletis’s drive to build a differentiated pipeline in long-acting obesity treatments.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc., incorporated in the Cayman Islands and listed in Hong Kong, is a biopharmaceutical company focused on developing innovative therapeutics. The group is increasingly active in metabolic and obesity-related drug programs, targeting significant unmet needs in global weight-management and chronic disease markets.
Average Trading Volume: 2,667,340
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.93B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.